Effect of Concurrent Chemoradiotherapy with Nituzumab Combined with Cisplatin on Prognosis and Quality of Life in Patients with Nasopharyn-geal Carcinoma
Objective To explore the effects of concurrent chemoradiotherapy with nituzumab plus cisplatin on the prognosis and quality of life of patients with nasopharyngeal carcinoma.Methods A total of 68 nasopharyngeal carci-noma patients admitted to the Oncology Department of the First People's Hospital of Changshu City from May 2021 to May 2023 were conveniently selected as the study objects,and were divided into control group and observation group according to different treatment methods,with 34 cases in each group.The control group received concurrent chemora-diotherapy with cisplatin,and the observation group was combined with nituzumab on the basis of the control group.The clinical efficacy,quality of life and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 64.71%(22/34),which was higher than that of the control group 38.23%(13/34),and the difference was statistically significant(χ2=4.769,P<0.05).Before treatment,there was no sig-nificant difference in quality of life scores between the two groups(P>0.05);after treatment,the life quality score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,the leukocyte count in the observation group was(5.11±0.44)×109/L,which was higher than that in the control group(3.74±0.35)×109/L,and the difference was statistically signifi-cant(t=14.208,P<0.05).Conclusion The concurrent chemoradiotherapy with nituzumab plus cisplatin can improve the quality of life of patients with nasopharyngeal carcinoma,and increase the effective rate of treatment with less adverse reactions.
NituzumabConcurrent chemoradiotherapy with cisplatinNasopharyngeal carcinomaQuality of lifeEfficientAdverse reaction
NETL
NSTL
万方数据
